Yan Chen
Chinese PLA General Hospital
8 Papers
56 Citations
Yan Chen is an academic researcher from Chinese PLA General Hospital. The author has contributed to research in topics: Internal medicine & Entecavir. The author has an hindex of 4, co-authored 7 publications.
Chat about Author
Papers
Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma
Yongping Yang,Chun-Ping Wang,Yin-Ying Lu,Wenlin Bai,Linjing An,Jianhui Qu,Xudong Gao,Yan Chen,Lin Zhou,Yu Wu,Yong-Yi Feng,Min-na Zhang,Xiujuan Chang,Jiyun Lv +13 more
TL;DR: US-guided percutaneous cryoablation is a relatively safe and effective therapy for selected HCC patients.
Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma
Jianhui Qu,Xiujuan Chang,Yin-Ying Lu,Wenlin Bai,Yan Chen,Lin Zhou,Zhen Zeng,Chun-Ping Wang,Linjing An,Li-yan Hao,Gui-lin Xu,Xudong Gao,Min Lou,Jiyun Lv,Yongping Yang +14 more
TL;DR: Overexpression of metastasis associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma as discussed by the authors, which is a type of liver cancer.
38
Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
Dong-Ming Ji,Yan Chen,Jingfeng Bi,Qinghua Shang,Huabao Liu,Jia-Bo Wang,Lin Tan,Jing Wang,Yongping Chen,Qin Li,Qing-Hua Long,Laicheng Song,Li Jiang,Guangming Xiao,Zujiang Yu,Liang Chen,Xiaodong Wang,Da Chen,Zhiqin Li,Zheng Dong,Yongping Yang +20 more
TL;DR: Wang et al. as discussed by the authors showed that entecavirus (ETV) plus BRC, an anti-fibrotic traditional Chinese medicine, can further reduce the risk of hepatocellular carcinoma (HCC) in treatment-naïve Chinese patients with chronic hepatitis B and an Ishak fibrosis score of ≥ 3 points derived from a parent double-blind randomized placebo-controlled trial.
32
Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients with Chronic Hepatitis B Treated with Entecavir: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial.
Guanghua Rong,Yong-Ping Chen,Zujiang Yu,Qin Li,Jingfeng Bi,Lin Tan,Dedong Xiang,Qinghua Shang,Chunliang Lei,Liang Chen,Xiaoyu Hu,Jing Wang,Huabao Liu,Wei Lu,Yan Chen,Zheng Dong,Wenlin Bai,Eric M. Yoshida,Nahum Méndez-Sánchez,Ke-Qin Hu,Xingshun Qi,Yongping Yang +21 more
TL;DR: Adding Biejia-Ruangan to the current standard treatment with NAs in CHB patients with advanced fibrosis or cirrhosis can improve liver fibrosis regression.
31
A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection.
Xiujuan Chang,Jing Wang,Yan Chen,Qing-Hua Long,Laicheng Song,Qin Li,Huabao Liu,Qinghua Shang,Zujiang Yu,Li Jiang,Guangming Xiao,Li Li,Liang Chen,Xiao-Dong Wang,Zhiqin Li,Da Chen,Zheng Dong,Linjing An,Lin Tan,Yong-Ping Chen,Yongping Yang +20 more
TL;DR: Wang et al. as mentioned in this paper developed a non-invasive model for identifying evident histological liver injury (EHLI) in HBeAg-positive chronic hepatitis B virus (HBV) infection patients.
21